Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer

Leigh Ellis, Sheng Yu Ku, Qiuhui Li, Gissou Azabdaftari, Joseph Seliski, Brian Olson, Colleen S. Netherby, Dean G. Tang, Scott I. Abrams, David W. Goodrich, Roberto Pili

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

INTRODUCTION: Transgenic mouse modeling is a favorable tool to reflect human prostate tumorigenesis and interactions between prostate cancer and the microenvironment. The use of GEMMs and derived cell lines represent powerful tools to study prostate cancer initiation and progression with an associated tumor microenvironment. Notably, such models provide the capacity for rapid preclinical therapy studies including immune therapies for prostate cancer treatment. METHODS: Backcrossing FVB Hi-MYC mice with C57BL/6N mice, we established a Hi-MYC transgenic mouse model on a C57BL/6 background (B6MYC). In addition, using a conditional reprogramming method, a novel C57BL/6 MYC driven prostate adenocarcinoma cell line was generated. RESULTS: Our results demonstrate that disease progression is significantly delayed in B6MYC when compared to their FVB counterparts. Current data also indicates infiltrating immune cells are present in pre-cancer lesions, prostate intraepithelial neoplasia (PIN). Further, immunophenotyping of this immune infiltrate demonstrates the predominant population as myeloid-derived suppressor cells (MDSC). Also, we successfully generated a B6MYC-CaP cell line, and determined that this new PCa cell line express markers of luminal epithelial lineage. DISCUSSION: This novel model of PCa provides a new platform to understand the cross talk between MYC driven prostate cancer and the microenvironment. Importantly, these models will be an ideal tool to support the clinical development of immunotherapy as well as other novel therapeutic strategies for prostate cancer treatment. Prostate 76:1192–1202, 2016.

Original languageEnglish (US)
Pages (from-to)1192-1202
Number of pages11
JournalProstate
Volume76
Issue number13
DOIs
StatePublished - Sep 15 2016

Fingerprint

Prostatic Neoplasms
Cell Line
Tumor Microenvironment
Prostate
Transgenic Mice
Therapeutics
Immunophenotyping
Inbreeding
Inbred C57BL Mouse
Immunotherapy
Disease Progression
Carcinogenesis
Adenocarcinoma
Population
Neoplasms

Keywords

  • cell line
  • mouse model
  • MYC
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Ellis, L., Ku, S. Y., Li, Q., Azabdaftari, G., Seliski, J., Olson, B., ... Pili, R. (2016). Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer. Prostate, 76(13), 1192-1202. https://doi.org/10.1002/pros.23206

Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer. / Ellis, Leigh; Ku, Sheng Yu; Li, Qiuhui; Azabdaftari, Gissou; Seliski, Joseph; Olson, Brian; Netherby, Colleen S.; Tang, Dean G.; Abrams, Scott I.; Goodrich, David W.; Pili, Roberto.

In: Prostate, Vol. 76, No. 13, 15.09.2016, p. 1192-1202.

Research output: Contribution to journalArticle

Ellis, L, Ku, SY, Li, Q, Azabdaftari, G, Seliski, J, Olson, B, Netherby, CS, Tang, DG, Abrams, SI, Goodrich, DW & Pili, R 2016, 'Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer', Prostate, vol. 76, no. 13, pp. 1192-1202. https://doi.org/10.1002/pros.23206
Ellis L, Ku SY, Li Q, Azabdaftari G, Seliski J, Olson B et al. Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer. Prostate. 2016 Sep 15;76(13):1192-1202. https://doi.org/10.1002/pros.23206
Ellis, Leigh ; Ku, Sheng Yu ; Li, Qiuhui ; Azabdaftari, Gissou ; Seliski, Joseph ; Olson, Brian ; Netherby, Colleen S. ; Tang, Dean G. ; Abrams, Scott I. ; Goodrich, David W. ; Pili, Roberto. / Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer. In: Prostate. 2016 ; Vol. 76, No. 13. pp. 1192-1202.
@article{0b4601eb3d174390873949b108d86c5f,
title = "Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer",
abstract = "INTRODUCTION: Transgenic mouse modeling is a favorable tool to reflect human prostate tumorigenesis and interactions between prostate cancer and the microenvironment. The use of GEMMs and derived cell lines represent powerful tools to study prostate cancer initiation and progression with an associated tumor microenvironment. Notably, such models provide the capacity for rapid preclinical therapy studies including immune therapies for prostate cancer treatment. METHODS: Backcrossing FVB Hi-MYC mice with C57BL/6N mice, we established a Hi-MYC transgenic mouse model on a C57BL/6 background (B6MYC). In addition, using a conditional reprogramming method, a novel C57BL/6 MYC driven prostate adenocarcinoma cell line was generated. RESULTS: Our results demonstrate that disease progression is significantly delayed in B6MYC when compared to their FVB counterparts. Current data also indicates infiltrating immune cells are present in pre-cancer lesions, prostate intraepithelial neoplasia (PIN). Further, immunophenotyping of this immune infiltrate demonstrates the predominant population as myeloid-derived suppressor cells (MDSC). Also, we successfully generated a B6MYC-CaP cell line, and determined that this new PCa cell line express markers of luminal epithelial lineage. DISCUSSION: This novel model of PCa provides a new platform to understand the cross talk between MYC driven prostate cancer and the microenvironment. Importantly, these models will be an ideal tool to support the clinical development of immunotherapy as well as other novel therapeutic strategies for prostate cancer treatment. Prostate 76:1192–1202, 2016.",
keywords = "cell line, mouse model, MYC, prostate cancer",
author = "Leigh Ellis and Ku, {Sheng Yu} and Qiuhui Li and Gissou Azabdaftari and Joseph Seliski and Brian Olson and Netherby, {Colleen S.} and Tang, {Dean G.} and Abrams, {Scott I.} and Goodrich, {David W.} and Roberto Pili",
year = "2016",
month = "9",
day = "15",
doi = "10.1002/pros.23206",
language = "English (US)",
volume = "76",
pages = "1192--1202",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "13",

}

TY - JOUR

T1 - Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer

AU - Ellis, Leigh

AU - Ku, Sheng Yu

AU - Li, Qiuhui

AU - Azabdaftari, Gissou

AU - Seliski, Joseph

AU - Olson, Brian

AU - Netherby, Colleen S.

AU - Tang, Dean G.

AU - Abrams, Scott I.

AU - Goodrich, David W.

AU - Pili, Roberto

PY - 2016/9/15

Y1 - 2016/9/15

N2 - INTRODUCTION: Transgenic mouse modeling is a favorable tool to reflect human prostate tumorigenesis and interactions between prostate cancer and the microenvironment. The use of GEMMs and derived cell lines represent powerful tools to study prostate cancer initiation and progression with an associated tumor microenvironment. Notably, such models provide the capacity for rapid preclinical therapy studies including immune therapies for prostate cancer treatment. METHODS: Backcrossing FVB Hi-MYC mice with C57BL/6N mice, we established a Hi-MYC transgenic mouse model on a C57BL/6 background (B6MYC). In addition, using a conditional reprogramming method, a novel C57BL/6 MYC driven prostate adenocarcinoma cell line was generated. RESULTS: Our results demonstrate that disease progression is significantly delayed in B6MYC when compared to their FVB counterparts. Current data also indicates infiltrating immune cells are present in pre-cancer lesions, prostate intraepithelial neoplasia (PIN). Further, immunophenotyping of this immune infiltrate demonstrates the predominant population as myeloid-derived suppressor cells (MDSC). Also, we successfully generated a B6MYC-CaP cell line, and determined that this new PCa cell line express markers of luminal epithelial lineage. DISCUSSION: This novel model of PCa provides a new platform to understand the cross talk between MYC driven prostate cancer and the microenvironment. Importantly, these models will be an ideal tool to support the clinical development of immunotherapy as well as other novel therapeutic strategies for prostate cancer treatment. Prostate 76:1192–1202, 2016.

AB - INTRODUCTION: Transgenic mouse modeling is a favorable tool to reflect human prostate tumorigenesis and interactions between prostate cancer and the microenvironment. The use of GEMMs and derived cell lines represent powerful tools to study prostate cancer initiation and progression with an associated tumor microenvironment. Notably, such models provide the capacity for rapid preclinical therapy studies including immune therapies for prostate cancer treatment. METHODS: Backcrossing FVB Hi-MYC mice with C57BL/6N mice, we established a Hi-MYC transgenic mouse model on a C57BL/6 background (B6MYC). In addition, using a conditional reprogramming method, a novel C57BL/6 MYC driven prostate adenocarcinoma cell line was generated. RESULTS: Our results demonstrate that disease progression is significantly delayed in B6MYC when compared to their FVB counterparts. Current data also indicates infiltrating immune cells are present in pre-cancer lesions, prostate intraepithelial neoplasia (PIN). Further, immunophenotyping of this immune infiltrate demonstrates the predominant population as myeloid-derived suppressor cells (MDSC). Also, we successfully generated a B6MYC-CaP cell line, and determined that this new PCa cell line express markers of luminal epithelial lineage. DISCUSSION: This novel model of PCa provides a new platform to understand the cross talk between MYC driven prostate cancer and the microenvironment. Importantly, these models will be an ideal tool to support the clinical development of immunotherapy as well as other novel therapeutic strategies for prostate cancer treatment. Prostate 76:1192–1202, 2016.

KW - cell line

KW - mouse model

KW - MYC

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84982860436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982860436&partnerID=8YFLogxK

U2 - 10.1002/pros.23206

DO - 10.1002/pros.23206

M3 - Article

C2 - 27225803

AN - SCOPUS:84982860436

VL - 76

SP - 1192

EP - 1202

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 13

ER -